Original Papers - Prostate Open access

Prognostic value of Ki67 and PSA-immunostaining in de novo metastatic hormone-sensitive prostate cancer

Authors

Published
31 March 2026
Section
Original Papers - Prostate
DOI
10.4081/aiua.2026.14731

Abstract

Introduction: Prostate cancer comprises biologically distinct subtypes. Ki67 reflects tumour proliferation, while prostate-specific antigen immunostaining (PSA-IHC) indicates differentiation, with low PSA-IHC suggesting dedifferentiation. The prognostic role of these markers in de novo metastatic hormone-sensitive prostate cancer (mHSPC) remains unclear.
Aim: To evaluate the prognostic value of Ki67 and PSA-IHC, individually and combined, in de novo mHSPC, and explore their relevance across treatment modalities.
Methods: We retrospectively analysed patients diagnosed with de novo mHSPC (2015-2020) who ultimately died from prostate cancer. Clinical data included age, ISUP grade, baseline and 7-month PSA, metastatic sites, and first-line treatment. Ki67 (MIB-1) and PSA-IHC were quantified as the percentage of positive nuclei and cytoplasmic staining, respectively. The 75th percentile defined high vs low expression. Endpoints were biochemical (bPFS), radiological (rPFS), castration-resistant progression-free survival (CRPC-FS), and overall survival (OS). Exploratory analyses were performed by treatment type: androgen receptor pathway inhibitors (ARPIs) or taxanes.
Results: Sixty-seven patients were included (median age 77 years). Most had high-grade tumours (ISUP ≥3, 83.6%). High Ki67 (>P75) correlated with shorter OS (10 vs 21 months, p=0.013). PSA-IHC >P75 predicted longer bPFS (13 vs 9 months, p=0.027). Combined stratification identified distinct prognostic groups (p=0.034): PSA-IHC low/Ki67 high defined a high-risk phenotype with poor outcomes, particularly among taxane-treated patients (p=0.006).
Conclusions: Combined Ki67 and PSA-IHC assessment refines risk stratification in de novo mHSPC, identifying a high-risk PSA-IHC low/Ki67 high subgroup with markedly worse prognosis. These findings warrant prospective validation.

Keywords

Supporting Agencies

Associação dos Amigos da Urologia e Transplantação Renal

Data Availability Statement

The datasets generated and/or analyzed during the current study are not publicly available due to ethical and legal restrictions imposed by the hospital's data protection policies, but de-identified data may be available from the corresponding author upon reasonable request and with appropriate institutional approvals.

References

  1. 1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74:123-156. DOI: https://doi.org/10.3322/caac.21834
  2. 2. Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: EAU-ESTRO-ESMO guidelines 2024. Eur Urol. 2024; 86:123-145.
  3. 3. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017; 377:338-351. DOI: https://doi.org/10.1056/NEJMoa1702900
  4. 4. Sweeney CJ, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015; 373:737-746. DOI: https://doi.org/10.1056/NEJMoa1503747
  5. 5. Fizazi K, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017; 377:352-360. DOI: https://doi.org/10.1056/NEJMoa1704174
  6. 6. Davis ID, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019; 381:121-131. DOI: https://doi.org/10.1056/NEJMoa1903835
  7. 7. Chi KN, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019; 381:13-24. DOI: https://doi.org/10.1056/NEJMoa1903307
  8. 8. Smith MR, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022; 386:1132-1142. DOI: https://doi.org/10.1056/NEJMoa2119115
  9. 9. Attard G, et al. Metastatic hormone-sensitive prostate cancer: biology and treatment evolution. Nat Rev Clin Oncol. 2022; 19:695-709.
  10. 10. Chi KN, et al. Treatment advances in metastatic hormone-sensitive prostate cancer: optimizing patient selection and sequencing. Nat Rev Urol. 2023; 20:283-297.
  11. 11. Parker CC, et al. Individualizing systemic therapy for advanced prostate cancer: challenges and opportunities. Nat Rev Urol. 2024;21:145-160.
  12. 12. Zhao SG, et al. Molecular subtyping of prostate cancer using transcriptomic and proteomic signatures. Eur Urol. 2023; 83:265-278.
  13. 13. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182:311-322. DOI: https://doi.org/10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
  14. 14. Cuzick J, Swanson GP, Fisher G, et al. Ki-67 is an independent predictor of prostate cancer death in routine clinical practice. Br J Cancer. 2012; 106:1026-1033.
  15. 15. Song Z, Zhou Q, Zhang JL, et al. Marker Ki67 as a prognostic biomarker for prostate cancer based on two cohorts. World J Clin Cases. 2024; 12:32-41. DOI: https://doi.org/10.12998/wjcc.v12.i1.32
  16. 16. Pasquale M, et al. Ki67, but not neuroendocrine differentiation, predicts prognosis in primary prostate cancer patients. Radiol Oncol. 2016; 50:313-320. DOI: https://doi.org/10.1515/raon-2016-0033
  17. 17. Blessin NC, et al. Automated Ki67 labeling index assessment in prostate cancer. J Pathol. 2023; 261:213-222.
  18. 18. Erbersdobler A, et al. Predictive value of prostate-specific antigen expression in tissue samples of prostate cancer. Hum Pathol. 2009;40:636-642.
  19. 19. Bonk S, et al. Prognostic and diagnostic role of PSA immunohistochemistry in prostate cancer. Oncol Rep. 2019; 42:2105-2113.
  20. 20. Spyratou V, et al. Ki67 and PSA expression are prognostic in metastatic hormone-naïve prostate cancer. Scand J Urol. 2023;57:289-297. DOI: https://doi.org/10.1080/0284186X.2023.2254480
  21. 21. Henshall SM, et al. Decreased expression of PSA and androgen receptor in advanced prostate cancer is associated with an aggressive phenotype. Mod Pathol. 2001; 14:1016-1024.
  22. 22. Pertega-Gomes N, et al. Loss of PSA expression combined with high proliferation index defines an aggressive molecular phenotype in prostate cancer. Mod Pathol. 2022;35:1183-1193.
  23. 23. Mori K, et al. Clinical outcomes of docetaxel versus ARPI as upfront therapy in mHSPC: impact of biological and pathological features. Eur Urol Oncol. 2024; 7:201-213.
  24. 24. Mateo J, et al. Biomarker-driven treatment selection in advanced prostate cancer: current status and future directions. Nat Rev Urol. 2024; 21:220-236.
  25. 25. Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of Ki-67 on outcomes in advanced prostate cancer. J Clin Oncol. 2021; 39:1358-1368.
  26. 26. Epstein JI, Amin MB, Beltran H, et al. Contemporary histologic grading of prostate cancer: insights from pathology and molecular studies. Hum Pathol. 2018; 79:140-152.
  27. 27. Khalaf DJ, Sunderland K, Eigl BJ, et al. Ki67 expression and outcomes in metastatic hormone-sensitive and castration-resistant prostate cancer. Eur Urol. 2019; 75:976-983.
  28. 28. Montironi R, Cimadamore A, Scarpelli M, et al. Histopathology and molecular features of androgen receptor-independent prostate cancer. Pathology. 2020; 52:68-78.
  29. 29. Humphrey PA. Histological variants of prostatic carcinoma and their clinical significance. Histopathology. 2017; 70:59-74. DOI: https://doi.org/10.1111/j.1365-2559.2011.04039.x
  30. 30. Beltran H, Hruszkewycz A, Scher HI, et al. The molecular landscape of neuroendocrine prostate cancer. Nat Med. 2019; 25:1608-1618.
  31. 31. Aparicio AM, Shen L, Tapia EL, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. J Clin Oncol. 2013;31:e2593-e2604.
  32. 32. Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Clin Cancer Res. 2019;25:6916-6924.
  33. 33. Tosoian JJ, Patel HD, Landis P, et al. Association of Ki-67 and PSA expression patterns with prostate cancer progression. BJU Int. 2021; 128:344-353.
  34. 34. Schweizer MT, Zhou XC, Wang H, et al. Molecular determinants of response to taxane chemotherapy in advanced prostate cancer. Clin Cancer Res. 2018; 24:4723-4731.
  35. 35. Abida W, Patnaik A, Campbell D, et al. Genomic correlates of clinical outcome in metastatic prostate cancer treated with taxanes. JAMA Oncol. 2023; 9:215-225.
  36. 36. Aggarwal R, Zhang T, Small EJ, et al. Molecular characterization of androgen receptor-independent prostate cancer. Nat Commun. 2021;12:1885.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2026 the Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.